Activity of Imipenem-Relebactam against Carbapenem-Resistant Escherichia coli Isolates from the United States in Relation to Clonal Background, Resistance Genes, Coresistance, and Region

Imipenem-relebactam (I-R) is a recently developed carbapenem-beta-lactamase inhibitor combination agent that can overcome carbapenem resistance, which has now emerged in , including sequence type 131 (ST131) and its fluoroquinolone-resistant 30R subclone, the leading cause of extraintestinal infecti...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Antimicrobial agents and chemotherapy 2020-04, Vol.64 (5)
Hauptverfasser:	Johnston, Brian D, Thuras, Paul, Porter, Stephen B, Anacker, Melissa, VonBank, Brittany, Vagnone, Paula Snippes, Witwer, Medora, Castanheira, Mariana, Johnson, James R
Format:	Artikel
Sprache:	eng
Schlagworte:	Anti-Bacterial Agents - pharmacology Azabicyclo Compounds - pharmacology Bacterial Proteins - antagonists & inhibitors beta-Lactamase Inhibitors - pharmacology beta-Lactamases Carbapenem-Resistant Enterobacteriaceae - drug effects Drug Resistance, Bacterial - drug effects Drug Resistance, Bacterial - genetics Epidemiology and Surveillance Escherichia coli - drug effects Escherichia coli - genetics Escherichia coli Infections - microbiology Genotype Geography Humans Imipenem - pharmacology Klebsiella pneumoniae - drug effects Klebsiella pneumoniae - genetics Microbial Sensitivity Tests Molecular Epidemiology United States - epidemiology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!